Bernstein Says Generic Copaxone Win Could Help Momenta Break through $20 Level

Loading...
Loading...
Momenta Pharmaceuticals
MNTA
shares spiked sharply Friday following news of a legal ruling invalidating Teva Pharmaceutical's
TEVA
patents on Copaxone in 2015 and partly invalidating its 2014 patents. Bernstein analyst Ronny Gal sees a 75 percent chance of the court decision being favorable for Momenta. The ruling could open the door to Momenta introducing a generic Copaxone within the next few months, according to Gal. If Momenta is able to introduce the first generic Copaxone by May 2014, Gal believes shares could be valued at $30. This is nearly twice the $15.35 level shares were trading at prior to Friday's spike. Gal believes a later release by Q4 2015 could spell upside of 30 percent from current levels to $23 per share. Gal rates Momenta at Outperform with a $20 price target.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsFDALegalAnalyst RatingsMovers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...